home / stock / ppbt / ppbt quote
Last: | $0.541 |
---|---|
Change Percent: | 0.0% |
Open: | $0.564 |
Close: | $0.541 |
High: | $0.57 |
Low: | $0.53 |
Volume: | 79,573 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.541 | $0.564 | $0.541 | $0.57 | $0.53 | 79,573 | 05-03-2024 |
$0.541 | $0.54 | $0.541 | $0.5797 | $0.5185 | 224,759 | 05-02-2024 |
$0.5231 | $0.529 | $0.5231 | $0.543 | $0.51635 | 37,073 | 05-01-2024 |
$0.519 | $0.539 | $0.519 | $0.539 | $0.4977 | 133,920 | 04-30-2024 |
$0.5101 | $0.5 | $0.5101 | $0.5199 | $0.4736 | 275,885 | 04-29-2024 |
$0.49 | $0.49 | $0.49 | $0.5376 | $0.475 | 176,664 | 04-26-2024 |
$0.516 | $0.52 | $0.516 | $0.6 | $0.49 | 1,694,703 | 04-25-2024 |
$0.5127 | $0.4871 | $0.5127 | $0.59 | $0.4503 | 266,544 | 04-24-2024 |
$0.49 | $0.46 | $0.49 | $0.49 | $0.43 | 82,150 | 04-23-2024 |
$0.4534 | $0.469 | $0.4534 | $0.469 | $0.4101 | 106,444 | 04-22-2024 |
$0.455 | $0.4699 | $0.455 | $0.4899 | $0.4433 | 52,314 | 04-19-2024 |
$0.461 | $0.4499 | $0.461 | $0.48 | $0.43 | 171,410 | 04-18-2024 |
$0.4343 | $0.4695 | $0.4343 | $0.4743 | $0.4108 | 281,429 | 04-17-2024 |
$0.4121 | $0.5634 | $0.4121 | $0.627 | $0.3023 | 1,003,270 | 04-16-2024 |
$0.583399 | $0.64 | $0.583399 | $0.6468 | $0.5402 | 184,782 | 04-15-2024 |
$0.6143 | $0.654 | $0.6143 | $0.67 | $0.61 | 46,189 | 04-12-2024 |
$0.615 | $0.6863 | $0.615 | $0.6995 | $0.6001 | 75,817 | 04-11-2024 |
$0.6863 | $0.69 | $0.6863 | $0.739 | $0.68 | 55,339 | 04-10-2024 |
$0.714999 | $0.71 | $0.714999 | $0.7482 | $0.7 | 97,733 | 04-09-2024 |
$0.714999 | $0.7 | $0.714999 | $0.7621 | $0.6763 | 61,274 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
Purple Biotech Ltd ADR (Sponsored) Level 3 Company Name:
PPBT Stock Symbol:
NASDAQ Market:
Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stag...
NT219 found to suppress cancer stem cells that promote drug resistance to KRAS G12C and KRAS G12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in responding patients in Phase 1 REHOVOT, Israel, March 28, 2024 (G...
Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity to the local tumor micro environment which increases the anticipated therapeutic window in patients REHOVOT, Israel, March 14, 2024...